PL3711767T3 - Preparat farmaceutyczny o doskonałej fotostabilności i właściwościach uwalniania leku - Google Patents

Preparat farmaceutyczny o doskonałej fotostabilności i właściwościach uwalniania leku

Info

Publication number
PL3711767T3
PL3711767T3 PL18877429.3T PL18877429T PL3711767T3 PL 3711767 T3 PL3711767 T3 PL 3711767T3 PL 18877429 T PL18877429 T PL 18877429T PL 3711767 T3 PL3711767 T3 PL 3711767T3
Authority
PL
Poland
Prior art keywords
pharmaceutical preparation
drug release
release properties
excellent photostability
photostability
Prior art date
Application number
PL18877429.3T
Other languages
English (en)
Inventor
Naomi Hayashi
Masato Gomi
Shohei Aikawa
Original Assignee
Shionogi & Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=66540251&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3711767(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shionogi & Co., Ltd. filed Critical Shionogi & Co., Ltd.
Publication of PL3711767T3 publication Critical patent/PL3711767T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K6/00—Preparations for dentistry
    • A61K6/80—Preparations for artificial teeth, for filling teeth or for capping teeth
    • A61K6/802—Preparations for artificial teeth, for filling teeth or for capping teeth comprising ceramics
    • A61K6/813—Preparations for artificial teeth, for filling teeth or for capping teeth comprising ceramics comprising iron oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/501—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/884—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Ceramic Engineering (AREA)
  • Plastic & Reconstructive Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Testing Resistance To Weather, Investigating Materials By Mechanical Methods (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
PL18877429.3T 2017-11-17 2018-11-15 Preparat farmaceutyczny o doskonałej fotostabilności i właściwościach uwalniania leku PL3711767T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017222068 2017-11-17
PCT/JP2018/042220 WO2019098259A1 (ja) 2017-11-17 2018-11-15 光安定性および溶出性に優れた医薬製剤

Publications (1)

Publication Number Publication Date
PL3711767T3 true PL3711767T3 (pl) 2026-02-16

Family

ID=66540251

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18877429.3T PL3711767T3 (pl) 2017-11-17 2018-11-15 Preparat farmaceutyczny o doskonałej fotostabilności i właściwościach uwalniania leku

Country Status (15)

Country Link
US (2) US12064438B2 (pl)
EP (2) EP3711767B1 (pl)
JP (2) JP6660644B2 (pl)
KR (1) KR102562514B1 (pl)
CN (1) CN111615390A (pl)
AR (1) AR113890A1 (pl)
AU (1) AU2018369241B2 (pl)
BR (1) BR112020009634B1 (pl)
CA (2) CA3082522C (pl)
ES (1) ES3058136T3 (pl)
IL (1) IL274625B (pl)
MX (1) MX2020004680A (pl)
PL (1) PL3711767T3 (pl)
TW (1) TWI795462B (pl)
WO (1) WO2019098259A1 (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020021059B1 (pt) 2018-04-24 2022-08-30 Shionogi & Co., Ltd Forma de dosagem sólida
US20220008429A2 (en) * 2019-03-22 2022-01-13 Shionogi & Co., Ltd. Treating influenza using substituted polycyclic pyridone derivatives and prodrugs thereof in a subject having influenza and a severe influenza condition
EP3714889A1 (en) * 2019-03-29 2020-09-30 F. Hoffmann-La Roche AG Baloxavir for the prevention of transmission of influenza virus
WO2021038480A1 (en) * 2019-08-27 2021-03-04 Janssen Pharmaceuticals, Inc. Combinations for treating influenza virus
WO2021084725A1 (ja) * 2019-10-31 2021-05-06 フジデノロ株式会社 検出装置、磁気組成物、及び、管理システム
CN111647005A (zh) * 2020-06-15 2020-09-11 安徽皓元药业有限公司 巴洛沙韦新晶型及其制备方法
JP7557863B2 (ja) * 2020-10-12 2024-09-30 共和薬品工業株式会社 イストラデフィリン含有医薬組成物
CN112730682B (zh) * 2020-12-25 2022-06-17 苏州海科医药技术有限公司 一种抗病毒药物临床研究血浆样本中奥司他韦及代谢物奥司他韦酸浓度的生物分析方法
CN114306261A (zh) * 2021-12-15 2022-04-12 澳美制药(苏州)有限公司 巴洛沙韦酯片及其制备方法
CN116036035A (zh) * 2023-02-28 2023-05-02 山东诚创蓝海医药科技有限公司 一种不含二氧化钛的富马酸伏诺拉生片剂制备方法
CN117969728B (zh) * 2024-02-01 2026-07-03 嘉实(湖南)医药科技有限公司 一种含聚维酮制剂中羟丙纤维素的检测方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2759293B1 (fr) 1997-02-11 1999-04-30 Ethypharm Lab Prod Ethiques Microgranules contenant du cisplatine, procede de fabrication, preparation pharmaceutique et utilisation en polychimiotherapie ou en association avec une radiotherapie
DE19831869A1 (de) * 1998-07-16 2000-01-20 Merck Patent Gmbh Farbgebung mit Perlglanzpigmenten im Lebensmittel- und Pharmabereich
DE60234812D1 (de) 2001-01-29 2010-02-04 Shionogi & Co Arzneipräparat, das als wirkstoff 5-methyl-1-phenyl-2-(1h)-pyridon enthält
WO2003057668A1 (en) * 2001-12-28 2003-07-17 Takeda Chemical Industries, Ltd. Nitrogenous cyclic ketone derivative, process for producing the same, and use
SE0203778D0 (sv) 2002-12-09 2002-12-09 Astrazeneca Ab A new oral immediated release dosage form
WO2004091600A1 (ja) * 2003-04-16 2004-10-28 Kyorin Pharmaceutical Co., Ltd. 経口固形製剤
EP1944029B1 (en) 2005-10-31 2011-12-21 Kowa Company, Ltd. Pharmaceutical preparation having excellent photostability
JO3048B1 (ar) * 2006-10-25 2016-09-05 Takeda Pharmaceuticals Co مشتقات متاستين واستخدامها
JP2008201712A (ja) 2007-02-20 2008-09-04 Ss Pharmaceut Co Ltd フィルムコーティング製剤
JPWO2008114859A1 (ja) 2007-03-22 2010-07-08 アステラス製薬株式会社 ピラゾール誘導体を含有する医薬組成物
EP2660239B1 (en) 2008-07-25 2016-11-23 VIIV Healthcare Company Chemical compounds as synthetic intermediates
JP5644167B2 (ja) 2009-04-21 2014-12-24 大正製薬株式会社 溶出改善されたケトチフェン又はその塩を含有する固形製剤
US20110009347A1 (en) * 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
US8748573B2 (en) * 2009-08-06 2014-06-10 Ironwood Pharmaceuticals, Inc. Formulations comprising linaclotide
CA2804506C (en) * 2010-07-06 2018-08-21 Janssen Pharmaceutica Nv Formulation for co-therapy treatment of diabetes
JP4803686B2 (ja) * 2010-08-31 2011-10-26 協和発酵キリン株式会社 苦味を呈する薬物を含有する顆粒および口腔内崩壊錠
WO2012144592A1 (ja) 2011-04-22 2012-10-26 アステラス製薬株式会社 固形医薬組成物
ES2643693T3 (es) * 2011-05-20 2017-11-23 Astrazeneca Uk Limited Composición farmacéutica de rosuvastatina cálcica
WO2013047795A1 (ja) * 2011-09-30 2013-04-04 アステラス製薬株式会社 粒子状医薬組成物
IN2014MN02029A (pl) 2012-04-24 2015-08-14 Daiichi Sankyo Companyltd
JP2015054822A (ja) 2013-09-10 2015-03-23 ニプロ株式会社 クロピドグレル含有錠剤およびその製造方法
JP2015054851A (ja) 2013-09-13 2015-03-23 大鵬薬品工業株式会社 被覆経口固形製剤
EA201690987A1 (ru) * 2013-11-13 2016-10-31 Новартис Аг Низкодозовые иммуностимулирующие ингибиторы mtor и их применения
WO2015090229A1 (en) * 2013-12-20 2015-06-25 Novartis Ag Regulatable chimeric antigen receptor
CN107709321A (zh) 2015-04-28 2018-02-16 盐野义制药株式会社 经取代的多环性吡啶酮衍生物及其前药
WO2016204291A1 (ja) * 2015-06-18 2016-12-22 共同印刷株式会社 ブリスターパック用積層体、及びそれを用いたブリスターパック
HK1254961A1 (en) * 2015-12-15 2019-08-02 Shionogi & Co., Ltd. Medicine for treating influenza characterized by comprising combination of cap-dependent endonuclease inhibitor with anti-influenza drug
BR112020021059B1 (pt) 2018-04-24 2022-08-30 Shionogi & Co., Ltd Forma de dosagem sólida

Also Published As

Publication number Publication date
AU2018369241A1 (en) 2020-06-18
US12064438B2 (en) 2024-08-20
EP4650773A3 (en) 2026-03-04
EP3711767C0 (en) 2025-11-12
EP3711767A1 (en) 2020-09-23
TWI795462B (zh) 2023-03-11
JP7251891B2 (ja) 2023-04-04
MX2020004680A (es) 2020-08-13
AU2018369241B2 (en) 2023-01-05
EP3711767B1 (en) 2025-11-12
TW201922259A (zh) 2019-06-16
IL274625A (en) 2020-06-30
US20200375998A1 (en) 2020-12-03
CA3082522A1 (en) 2019-05-23
EP4650773A2 (en) 2025-11-19
KR20200089290A (ko) 2020-07-24
JPWO2019098259A1 (ja) 2019-12-12
EP3711767A4 (en) 2021-12-01
WO2019098259A1 (ja) 2019-05-23
ES3058136T3 (en) 2026-03-09
JP6660644B2 (ja) 2020-03-11
KR102562514B1 (ko) 2023-08-03
CA3299815A1 (en) 2026-04-09
JP2020079283A (ja) 2020-05-28
BR112020009634A2 (pt) 2020-11-10
AR113890A1 (es) 2020-06-24
IL274625B (en) 2022-08-01
US20240366622A1 (en) 2024-11-07
CA3082522C (en) 2026-07-07
CN111615390A (zh) 2020-09-01
BR112020009634B1 (pt) 2022-08-30

Similar Documents

Publication Publication Date Title
NL301217I2 (nl) tirzepatide en farmaceutisch aanvaardbare zouten daarvan
HUS2100006I1 (hu) Avapritinib és gyógyászatilag elfogadható sói
EP3558424A4 (en) DRUG DELIVERY SYSTEMS AND METHODS
DK3493862T3 (da) Lægemiddelindgivelsesanordning
DK3703785T3 (da) Lægemiddelindgivelsesanordning
HUE054103T2 (hu) Izokinolin-3-il-karboxamidok, ezek elõállítása és alkalmazása
EP3711767C0 (en) Pharmaceutical preparation exhibiting excellent photostability and drug release properties
LT2986304T (lt) Farmacinė kompozicija, gydymo būdai ir jų panaudojimas
EP3454899C0 (en) PHARMACEUTICAL COMPOSITION
PL3518892T3 (pl) Preparat farmaceutyczny zawierający związek insuliny
IL280184A (en) Drug delivery devices
DK3558438T3 (da) Lægemiddelindgivelsesanordning
DK3554534T3 (da) Farmaceutisk sammensætning omfattende insulin
HUE053963T2 (hu) Béta-guanidinopropionsav gyógyszerészetileg elfogadható, javított tulajdonságokkal rendelkezõ sói és ezek alkalmazásai
HUE046033T2 (hu) Új kriptoficin vegyületek és konjugátumok, elõállításuk és gyógyászati alkalmazásuk
EP3603642A4 (en) PHARMACEUTICAL PREPARATION
MA42303A (fr) Formulations pharmaceutiques
PL3881833T3 (pl) Tabletki o natychmiastowym uwalnianiu zawierające lek i sposoby wytwarzania tabletek
DK3558423T3 (da) Medikamentadministrationsanordning
EP3313187A4 (en) FORMULATION WITH DELAYED RELEASE AND TABLETS MANUFACTURED THEREFROM
HUE062326T2 (hu) Fokozott stabilitású gyógyászati készítmény
DK3236934T3 (da) Farmaceutisk sammensætning, fremstilling og anvendelser deraf
EP3583943A4 (en) PHARMACEUTICAL COMPOSITION
DK3229843T3 (da) Farmaceutisk sammensætning, præparat og anvendelser deraf
DK3681564T3 (da) Lægemiddeladministrationsanordning